Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Bristol-Myers Squibb
Medical College of Wisconsin
Incyte Corporation
Incyte Corporation
Janssen Research & Development, LLC
University of California, Irvine
Bristol-Myers Squibb
Sun Yat-sen University
Hoffmann-La Roche
Centre Leon Berard
Northwell Health
GlaxoSmithKline
J-Pharma Co., Ltd.
Shanghai Zhongshan Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
UNICANCER
UNICANCER
Massachusetts General Hospital
Sun Yat-sen University
GERCOR - Multidisciplinary Oncology Cooperative Group
Weill Medical College of Cornell University
Nanjing Tianyinshan Hospital
McGill University Health Centre/Research Institute of the McGill University Health Centre
St. Olavs Hospital
Azienda Ospedaliera Universitaria Integrata Verona
Alethia Biotherapeutics
The Methodist Hospital Research Institute
University Hospital Tuebingen
Merus B.V.
UNICANCER
Centre Hospitalier Universitaire de Besancon
Seoul National University Hospital
Fudan University
UNICANCER
Beijing Tsinghua Chang Gung Hospital
Gustave Roussy, Cancer Campus, Grand Paris
Fudan University
Sixth Affiliated Hospital, Sun Yat-sen University
Sixth Affiliated Hospital, Sun Yat-sen University
Sun Yat-sen University
Sun Yat-sen University
Catharina Ziekenhuis Eindhoven
Celyad Oncology SA
Sun Yat-sen University
Xiangya Hospital of Central South University
Tanta University